The approval is nominally for all HCV genotypes; however (as previously noted on this board), the product is primarily intended for GT3 patients. There is no 8-week treatment option.
Today is the PDUFA date.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.